一种核桃粕抗结肠癌肽及其应用
Walnut meal protein peptide VSLP was prepared and screened by enzymatic hydrolysis. Combined with network pharmacology and molecular docking methods, it solved the problems of adverse reactions and low bioavailability of existing anticancer drugs, and achieved high-efficiency inhibition and apoptosis induction of colon cancer cells, providing a safe and effective anticancer treatment option.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- YUNNAN AGRICULTURAL UNIVERSITY
- Filing Date
- 2023-05-31
- Publication Date
- 2026-07-17
AI Technical Summary
Existing anticancer drugs have adverse effects on organs such as the kidneys, heart, and gonads. Furthermore, long-term use can lead to multiple drug resistance, low drug bioavailability, and poor cell specificity, resulting in an increased probability of cancer recurrence. Moreover, existing methods are not efficient at screening peptides with anti-colon cancer activity.
Walnut meal peptides were prepared by enzymatic hydrolysis and purified by ultrafiltration. Val-Ser-Leu-Pro (VSLP), a walnut meal protein peptide with anti-colon cancer activity, was screened using network pharmacology, bioinformatics, and molecular docking methods. Targets were predicted using the SwissADME, Swiss Target Prediction, GeneCards, Drugbank, and DisGeNET databases. A target network was constructed using CytoScape, and functional annotation and pathway enrichment were performed using the David database. Molecular docking was used to verify the binding of the peptides to the targets.
The screened walnut meal protein peptide VSLP showed significant inhibitory effects on the proliferation of human colon cancer HCT116 cells, with an IC50 value of 214.9 μM. It also showed strong inhibitory activity against other colon cancer cell lines, achieving anti-cancer effects by inducing apoptosis and inhibiting proliferation.
Smart Images
Figure CN116425831B_ABST